Enzon Pharmaceuticals - R&D Services

Enzon, Inc.
Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON?, marketed by Schering-Plough, and ABELCET?, ONCASPAR?, ADAGEN?, and DEPOCYT?, marketed in North America by Enzon?s specialized sales force.
Enzon?s science-driven strategy includes an extensive drug development program that leverages the Company?s macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA?) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional products and technologies.
Our proprietary drug development programs focus on engineering biologic therapeutics or macromolecules. Since our inception, our core expertise has been in modifying large molecule biologics through macromolecular engineering in order to increase efficacy, improve safety profiles, generate improved versions of existing therapeutics, and advance these drugs through development to commercialization
Macromolecular Engineering is the process by which the pharmaceutical features of macromolecules, such as proteins, peptides or oligonucleotides are optimized through processes that include site-specific amino acid exchanges, site-selective modification with our proprietary PEG (polyethylene glycol) technology, or antibody engineering through our proprietary SCA (single-chain antibody) technology. Given the advancements in genomics and proteomics over the recent years, we believe a wealth of opportunity exists across this field. These advancements have resulted in the discovery of a significant number of specific and highly biologically active macromolecules, which often lack the features needed for effective therapeutics, such as adequate circulating half-life, physical or metabolic stability, and overcoming adverse immunological responses that can render a compound ineffective. Through the application of our Macromolecular Engineering expertise, we have transformed several macromolecules into successful therapeutics, including PEG-INTRON, ONCASPAR, and ADAGEN.
In addition to our internal drug research and development activities, we are also committed to broadening our pipeline and technology base through in-licensing opportunities and strategic partnerships.
Enzon, Inc.
20 Kingsbridge Road
Piscataway, NJ 08854
(732) 980-4500 (phone)
(732) 980-5911 (fax)